Dual-view endoscopic probe

 描述（由申请人提供）：结肠癌是美国和海外癌症死亡的主要原因。结肠镜检查是首选的筛查方法，在美国估计每年花费超过200亿美元。不幸的是，许多病变被错过，因为癌前生长仍然隐藏在结肠的褶皱和弯曲后面。目前增加视场的方法是无效的，并且一些是非常昂贵的，这阻碍了这些方法在临床实践中的采用。一种专有的双视图成像方法已经开发出来，照明和图像向前以及向后在360度，并产生一个单一的图像。已经成功开发了概念原型的验证，但是太大而不能与结肠镜一起使用。Omniscient LLC将从亚利桑那大学获得该方法的许可，并构建一个双视图光学探头，该探头足够小，可以通过标准结肠镜检查的活检通道。全知有限责任公司将开发软件，结合在一个单一的视频显示和优化图像质量的两个视图。该探头将在标准结肠镜模型中进行测试，模拟息肉位于容易看到的区域以及隐藏在前视图中的区域。探头将穿过标准结肠镜检查的活检通道，并将其性能与单独的标准结肠镜检查进行比较。该一期STTR项目的成功完成将产生一种双视图探头，可用于标准结肠镜检查，并适用于临床测试。

 DESCRIPTION (provided by applicant): Colon cancer is a leading cause of cancer death in the United States and overseas. Colonoscopy is the preferred screening method at an estimated annual cost of over $20 billion in the US. Unfortunately, many lesions are missed because pre-cancerous growths remain hidden from view behind folds and flexures of the colon. Current methods of increasing the field of view are ineffective and some are very expensive, which hampers adoption of these methods into clinical practice. A proprietary dual-view imaging method has been developed that illuminates and images forward as well as backwards in 360 degrees, and produces a single image. A proof of concept prototype has been successfully developed, but is too large to be used with a colonoscopy. Omniscient LLC will license the method from the University of Arizona and construct a dual-view optical probe that is small enough to be passed through the biopsy channel of a standard colonoscopy. Omniscient LLC will develop software which combines both views in a single video display and optimize image quality. The probe will be tested in standard colonoscopy models with simulated polyps in areas that are easy to see as well as those hidden from forward view. The probe will be passed through the biopsy channel of the standard colonoscopy and its performance will be compared to that of the standard colonoscopy alone. Successful completion of this Phase I STTR project will lead to a dual-view probe which can be used with standard colonoscopy and is suitable for clinical testing.